Resource data sheet
DNA Bank Top
Please review the QC test results indicated by check icon below as well as clone information before placing your order.

pCMFlag_hsIL2RG (#RDB07006)

Expression vector of human IL2RG.

Alternative name SET-0197_4
Clone info. Expression vector of human IL2RG. Expression has not yet been confirmed.
Comment Derived from Sugano TMS05755. PCR cloning, forward primer: atgttgaagccatcattaccattc; reverse primer: ttcaggtttcaggctttaggg.
Vector backbone pCMV_S-FLAG (RDB05956) (Plasmid)
Size of vector backbone 5.5 kb
Selectable markers Amp^r (E. coli), Neo^r (mammalian cell)
Growth conditions 37C, LB+Amp
Gene/insert name Human IL2RG/IL-2R gamma cDNA
Depositor|Developer DNA Bank, |
 

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
MTA, for use for for-profit purpose [Word]
Please visit Information of Request for Distribution.[link] 
Terms and conditions for distribution The RECIPIENT agrees to describe RIKEN BRC as the source of the MATERIAL and cite Gene 200, 149-156, 1997 in any publication.
Additional terms and conditions:
Regrding pRc/CMV:
a) The modified pRc/CMV, and their descendants (collectively, LIFE MATERIALS), should be used for pre-clinical/non-human, research use only.
b) LIFE MATERIALS shall not be used for any commercial purposes.
c) LIFE MATERIALS shall not be transferred beyond the specified recipient.
d) Recipient must contact Thermo Fisher Scientific Inc. at outlicense@thermofisher.com for any desired use of LIFE MATERIALS beyond the scope of a) to c) above.
提供案内 (日本国内) [open/close]

必要書類
提供依頼書  [依頼書の記入例 ]
提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ]
提供同意書 (MTA, 営利目的用)[Word]
手続きの概要は、「提供申込みについて[link]」をご覧ください。
MTAに書く使用条件 発表に際し、理研BRCから入手したことを明記し、指定する文献(Gene, 200, 149-156 (1997))を引用すること。
付加的使用条件:
pRc/CMVについて:
a) The modified pRc/CMV, and their descendants (collectively, LIFE MATERIALS), should be used for pre-clinical/non-human, research use only.
b) LIFE MATERIALS shall not be used for any commercial purposes.
c) LIFE MATERIALS shall not be transferred beyond the specified recipient.
d) Recipient must contact Thermo Fisher Scientific Inc. at outlicense@thermofisher.com for any desired use of LIFE MATERIALS beyond the scope of a) to c) above.

Catalog # Resource name Shipping form Fee
RDB07006 pCMFlag_hsIL2RG DNA solution JPY 9,460 (not-for-profit academic purpose)
JPY 18,920 (for-profit-research purpose)
plus cost of shipping containers, dry ice (if required) and shipping charge

Please review the QC test results indicated by check icon below as well as clone information before placing your order.

How to cite this biological resource

Materials & Methods section:

The pCMFlag_hsIL2RG was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB07006).

Reference section:

Further references such as user reports and related articles (go to bottom)


QC test results

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check icon as well as clone information before placing your order.

Test sheet RDB13004_A4Jv.pdf check

Nucleotide sequence of a portion of this resource (if available).

Primer: CMV-Forward
Sequence file: RDB13004_A4Jva.seq check
>07006_13004_A4Jv_CMV-Forward_E07_13.ab1
    1 CTTCCACTCC GCCCATTGAC GCAATGGGCG GTAGGCGTGT ACGGTGGGAG GTCTATATAA
   61 GCAGAGCTCT CTGGCTAACT AGAGAACCCA CTGCTTACTG GCTTATCGAA ATTAATACGA
  121 CTCACTATAG GGAGACCCAA GCTGAATTCA CCATGGACTA CAAGGACGAT GACGATAAGG
  181 CGGCCATGTT GAAGCCATCA TTACCATTCA CATCCCTCTT ATTCCTGCAG CTGCCCCTGC
  241 TGGGAGTGGG GCTGAACACG ACAATTCTGA CGCCCAATGG GAATGAAGAC ACCACAGCTG
  301 ATTTCTTCCT GACCACTATG CCCACTGACT CCCTCAGTGT TTCCACTCTG CCCCTCCCAG
  361 AGGTTCAGTG TTTTGTGTTC AATGTCGAGT ACATGAATTG CACTTGGAAC AGCAGCTCTG
  421 AGCCCCAGCC TACCAACCTC ACTCTGCATT ATTGGTACAA GAACTCGGAT AATGATAAAG
  481 TCCAGAAGTG CAGCCACTAT CTATTCTCTG AAGAAATCAC TTCTGGCTGT CAGTTGCAAA
  541 AAAAGGAGAT CCACCTCTAC CAAACATTTG TTGTTCAGCT CCAGGACCCA CGGGAACCCA
  601 GGAGACAGGC CACACAGATG CTAAAACTGC AGAATCTGGT GATCCCCTGG GCTCCAGAGA
  661 ACCTAACACT TCACAAACTG AGTGAATCCC AGCTAGAACT GAACTGGAAC AACAGATTCT
  721 TGAACCACTG TTTGGAGCAC TTGGTGCAGT ACCGGACTGA CTGGGACCAC AGCTGGACTG
  781 AACAATCAGT GGATTATAGA CATAAGTTCT CCTTGCCTAG TGTGGATGGG CAGAAACGCT
  841 ACACGTTTCG TGTTCGGAGC CGCTTTAACC CACTCTGTGG AAGTGCTCAG CATTGGAGTG
  901 AATGGAGCCA CCCAATCCAC TGGGGGGAGC AATACTTCAA AAGAGAATCC TTTCCTGTTT
  961 GCATTGGAAA GCCGTGGTTA TCTCTGTTGG CTCCATGGGA TTGATTATCA GCCTTTCTCT
 1021 GTGTGTATTT CTGGCTGGGA ACGGAACGAT GCCCCGAATT TCCCCACCCT GAAGATTAGA
 1081 GGAATCTTGT TACTGATACC ACGGACCTTT TCCACTGCAG TTGATGGTGT CTAACGGACG
1141 TTGGGCTTGG AGAAGTCCCT GC
//
Primer: BGH_rev
Sequence file: RDB13004_A4Jvb.seq check
>07006_13004_A4Jv_BGH_rev_F07_16.ab1
    1 GCTGGCATTA GGTGCCTATA GAATAGGGCC CTCTAGATGC ATGCTCGAGC GGCCTTCAGG
   61 TTTCAGGCTT TAGGGTGTAA CATGGGGGGG CCCAGTAGGG GCTATGCTGG TTGCATGGGG
  121 AGGCCCCAGG CCCCTCCCCA AGGGCCCCTC CTTTTGGGGG AATCTCACTG ACGAGGCAGA
  181 GTCGTTCACT GTAGTCTGGC TGCAGACTCT CAGCCAGTCC CTTAGACACA CCACTCCAGG
  241 CCGAAAAGTT CCCGTGGTAT TCAGTAACAA GATCCTCTAG GTTCTTCAGG GTGGGAATTC
  301 GGGGCATCGT CCGTTCCAGC CAGAAATACA CACAGAGAAG GCTGATAATC AATCCCATGG
  361 AGCCAACAGA GATAACCACG GCTTCCAATG CAAACAGGAA AGGATTCTCT TTTGAAGTAT
  421 TGCTCCCCCA GTGGATTGGG TGGCTCCATT CACTCCAATG CTGAGCACTT CCACAGAGTG
  481 GGTTAAAGCG GCTCCGAACA CGAAACGTGT AGCGTTTCTG CCCATCCACA CTAGGCAAGG
  541 AGAACTTATG TCTATAATCC ACTGATTGTT CAGTCCAGCT GTGGTCCCAG TCAGTCCGGT
  601 ACTGCACCAA GTGCTCCAAA CAGTGGTTCA AGAATCTGTT GTTCCAGTTC AGTTCTAGCT
  661 GGGATTCACT CAGTTTGTGA AGTGTTAGGT TCTCTGGAGC CCAGGGGATC ACCAGATTCT
  721 GCAGTTTTAG CATCTGTGTG GCCTGTCTCC TGGGTTCCCG TGGGTCCTGG AGCTGAACAA
  781 CAAATGTTTG GTAGAGGTGG ATCTCCTTTT TTTGCAACTG ACAGCCAGAA GTGATTTCTT
  841 CAGAGAATAG ATAGTGGCTG CACTTCTGGA CTTTATCATT ATCCGAGTTC TTGTACCAAT
  901 AATGCAGAGT GAGGTTGGTA GGCTGGGGCT CAGAGCTGCT GTTCCAAGTG CAATTCATGT
  961 ACTCGACATT GAACACAAAA CACTGAACCC TCTGGGAGGG GCAGAGTGGA AAACACTGAG
 1021 GGAGTCAGTG GGGCATAGTG GTCAGAGAAT CAGCTGTGGT GTCTCATCCC ATTGGGCGTC
 1081 AGAATTGTCG TGATCAGCCC AACTCCCAGG CAGGGCCAGC CTGCAAGCAT TAAGAGGGCA
1141 TGGTGTGCAT
//

Please visit Sequencing and PCR primers for primer information.


References

Original, user report and related articles